This Article Full Text Full Text (PDF) All Versions of this Article: 95/12/e110    most recent 01.RES.0000150368.56660.4fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blaschke, F. Articles by Bruemmer, D. Search for Related Content PubMed PubMed Citation Articles by Blaschke, F. Articles by Bruemmer, D. Related Collections Smooth muscle proliferation and differentiation

(Circulation Research. 2004;95:e110.)
© 2004 American Heart Association, Inc.

UltraRapid Communications

Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries

Florian Blaschke, Olli Leppanen, Yasunori Takata, Evren Caglayan, Joey Liu, Michael C. Fishbein, Kai Kappert, Keiichi I. Nakayama, Alan R. Collins, Eckart Fleck, Willa A. Hsueh, Ronald E. Law, Dennis Bruemmer

From the Division of Endocrinology, Diabetes, and Hypertension (F.B., Y.T., E.C., J.L., W.A.H., R.E.L.) and the Department of Pathology (M.C.F.), David Geffen School of Medicine, University of California, Los Angeles; Department of Medicine/Cardiology (F.B., E.F.), German Heart Institute, Berlin, Germany; Division of Vascular Surgery (O.L.), University Hospital, Uppsala, Sweden; Department of Pathology-Oncology (K.K.), Karolinska Institute, Stockholm, Sweden; Department of Molecular and Cellular Biology (K.I.N.), Kyushu University, Fukuoka, Japan; and Division of Endocrinology and Molecular Medicine (D.B.), University of Kentucky College of Medicine, Lexington. Present address for R.E.L. is Takeda Pharmaceuticals of North America, Lincolnshire, Ill.

Correspondence and requests for reprints to Dennis Bruemmer, MD, University of Kentucky College of Medicine, Department of Internal Medicine, Division of Endocrinology and Molecular Medicine, Wethington Health Sciences Bldg, Rm 575, 900 S Limestone St, Lexington, KY 40536-0200. E-mail Dennis.Bruemmer{at}uky.edu

The liver X receptors and ß (LXR and LXRß) are important regulators of cholesterol homeostasis in liver and macrophages. Synthetic LXR ligands prevent the development of atherosclerosis in murine models; however, the potential functional relevance of LXRs in vascular smooth muscle cells (VSMCs) has not been investigated. In the present study, we demonstrate that LXRs are expressed and functional in primary human coronary artery VSMCs (CASMCs). LXR ligands inhibited mitogen-induced VSMC proliferation and G₁S phase progression of the cell cycle. Inhibition of G₁ exit by LXR ligands was accompanied by a dose-dependent inhibition of retinoblastoma protein (Rb) phosphorylation, which functions as the key switch for G₁S cell cycle progression. LXR ligands suppressed mitogen-induced degradation of the cyclin-dependent kinase inhibitor p27^Kip1, attenuated cyclin D1 and cyclin A expression, and inhibited the expression of S phase-regulatory minichromosome maintenance protein 6. Stabilization of p27^kip1 by LXR ligands was mediated by supressing the transcriptional activation of the S phase kinase–associated protein 2 (Skp2), an F-box protein that targets p27^Kip1 for degradation. Inhibition of Rb phosphorylation and G₁S cell cycle progression by LXR ligands was reversed in VSMCs overexpressing Skp2, indicating that Skp2 as an upstream regulator of p27^Kip1 degradation plays a central role in LXR ligand–mediated inhibition of VSMC proliferation. Furthermore, adenovirus-mediated overexpression of the S phase transcription factor E2F, which is released after Rb phosphorylation, reversed the inhibitory effect of LXR ligands on VSMC proliferation and S phase gene expression, suggesting that the primary mechanisms by which LXR ligands inhibit VSMC proliferation occur upstream of Rb phosphorylation. Finally, neointima formation in a model of rat carotid artery balloon injury was significantly attenuated after treatment with the LXR ligand T1317 compared with vehicle-treated animals. These data demonstrate that LXR ligands inhibit VSMC proliferation and neointima formation after balloon injury and suggest that LXR ligands may constitute a novel therapy for proliferative vascular diseases. The full text of this article is available online at http://circres.ahajournals.org.

Key Words: vascular smooth muscle cell • liver X receptor • arterial injury

This article has been cited by other articles:

				R. Geyeregger, M. Shehata, M. Zeyda, F. W. Kiefer, K. M. Stuhlmeier, E. Porpaczy, G. J. Zlabinger, U. Jager, and T. M. Stulnig Liver X receptors interfere with cytokine-induced proliferation and cell survival in normal and leukemic lymphocytes J. Leukoc. Biol., November 1, 2009; 86(5): 1039 - 1048. [Abstract] [Full Text] [PDF]

				L.-L. Vedin, S. A. Lewandowski, P. Parini, J.-A. Gustafsson, and K. R. Steffensen The oxysterol receptor LXR inhibits proliferation of human breast cancer cells Carcinogenesis, April 1, 2009; 30(4): 575 - 579. [Abstract] [Full Text] [PDF]

				B. M. Proctor, X. Jin, T. S. Lupu, L. J. Muglia, C. F. Semenkovich, and A. J. Muslin Requirement for p38 Mitogen-Activated Protein Kinase Activity in Neointima Formation After Vascular Injury Circulation, August 5, 2008; 118(6): 658 - 666. [Abstract] [Full Text] [PDF]

				I. Imayama, T. Ichiki, D. Patton, K. Inanaga, R. Miyazaki, H. Ohtsubo, Q. Tian, K. Yano, and K. Sunagawa Liver X Receptor Activator Downregulates Angiotensin II Type 1 Receptor Expression Through Dephosphorylation of Sp1 Hypertension, June 1, 2008; 51(6): 1631 - 1636. [Abstract] [Full Text] [PDF]

				I. P. Torra, N. Ismaili, J. E. Feig, C.-F. Xu, C. Cavasotto, R. Pancratov, I. Rogatsky, T. A. Neubert, E. A. Fisher, and M. J. Garabedian Phosphorylation of Liver X Receptor {alpha} Selectively Regulates Target Gene Expression in Macrophages Mol. Cell. Biol., April 15, 2008; 28(8): 2626 - 2636. [Abstract] [Full Text] [PDF]

				M. Nilsson, K. Dahlman-Wright, C. Karelmo, J.-A. Gustafsson, and K. R. Steffensen Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter Nucleic Acids Res., July 10, 2007; (2007) gkm492v1. [Abstract] [Full Text] [PDF]

				F. Blaschke, Y. Takata, E. Caglayan, A. Collins, P. Tontonoz, W. A. Hsueh, and R. K. Tangirala A Nuclear Receptor Corepressor-Dependent Pathway Mediates Suppression of Cytokine-Induced C-Reactive Protein Gene Expression by Liver X Receptor Circ. Res., December 8, 2006; 99(12): e88 - e99. [Abstract] [Full Text] [PDF]

				P. I. Bonta, C. M. van Tiel, M. Vos, T. W.H. Pols, J. V. van Thienen, V. Ferreira, E. K. Arkenbout, J. Seppen, C. A. Spek, T. van der Poll, et al. Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2288 - 2288. [Abstract] [Full Text] [PDF]